Smart-money news
What whales, hedge funds and billionaires are doing right now — from official filings
Ken Griffin Shifts Investments: New Positions in AstraZeneca and Pinnacle Financial
The head of leading hedge fund Citadel Advisors opens new positions in pharmaceuticals and finance, divesting from technology and data storage.
Ken Griffin, manager of the colossal hedge fund Citadel Advisors, made substantial changes to the fund's investment portfolio in the first quarter of 2026. According to the 13F filing published on March 31, 2026, Citadel initiated a new position in the pharmaceutical manufacturer AstraZeneca PLC ($AZN) amounting to $519 million. Concurrently, another position was opened in Pinnacle Financial Partners Inc. ($PNFP), a financial services company, valued at $285 million.
These moves come alongside a complete exit from previous holdings. Citadel sold its entire position in Seagate HDD Cayman ($STX), a data storage company, which previously amounted to $336 million. Additionally, the full holding in CyberArk Software Ltd. ($CYBR), an Israeli cybersecurity company, valued at $331 million, was divested.
The movements in Griffin's portfolio exemplify the dynamic strategy of large hedge funds, which make significant adjustments across various sectors according to their forecasts. Individual traders can learn from this about the importance of flexibility in an investment portfolio and the ability to identify opportunities in diverse sectors. It should be remembered that 13F filings are published with a delay of up to 45 days, and therefore reflect the portfolio's status at the end of the previous quarter.
Sources
Stories are auto-written from official filings (SEC, congressional disclosures, USAspending) and financial press, with AI assistance. Inaccuracies are possible; 13F filings lag by up to 45 days. For research only — not investment advice or a recommendation.
